Inflammatory Breast Cancer
Inflammatory breast cancer (IBC) represents the most virulent form of breast cancer, characterized by involvement of the skin and rapid progression of the disease. Management involves careful coordination of all multidisciplinary modalities, including imaging, systemic chemotherapy, surgery, and radiation therapy. The use of neoadjuvant chemotherapy has contributed significantly to improvement in overall survival since the first descriptions of this entity and has made the role of locoregional therapy, including surgery and radiation critical to continued improvements in this disease. In this article, we examine the unique epidemiology and pathology of IBC and review the various treatment modalities noting the significance of a multimodality approach and delineating each of the specific components. Moreover, we briefly describe the current research in IBC that will hopefully contribute further to improve systemic therapies.
To access this article, please choose from the options below
Supported by Komen Foundation Promise grant KGO81287, the University of Texas Institutional Research grants K12-5611B through the University of Texas Health Sciences Centre from the National Institute of Health, and the University of Texas M. D. Anderson Cancer Center grant no. R01CA138239-01; IRG.
PII: S1053-4296(09)00045-9
doi:10.1016/j.semradonc.2009.05.008
Published by Elsevier Inc.
